LasikaChandradattaSeneviratneMD

Oncology • Los Angeles, CA

Physician

Join to view full profile

Dr. Seneviratne is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Seneviratne's full profile

Already have an account?

Office
1245 Wilshire Blvd
Suite 303
Los Angeles, CA 90017
Phone+1 213-977-1214

Fax+1 213-482-8868

Education & Training

University of Southern California/LAC+USC Medical CenterFellowship, Hematology, 2000 - 2001
University of Southern California/LAC+USC Medical CenterFellowship, Medical Oncology, 1999 - 2000
University of Southern California/LAC+USC Medical CenterFellowship, Hematology, 1998 - 1999
University of Southern California/Los Angeles General Medical Center (USC/LA General)Residency, Internal Medicine, 1995 - 1998
University of Colombo Faculty of MedicineClass of 1992

Certifications & Licensure

CA State Medical License 1996 - 2026
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification OncoEMR, Altos Solutions, Inc., 2011-2013
Super Doctor SuperDoctors.com

Clinical Trials

LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib Start of enrollment: 2013 Jun 28
Completed
Phase 3
A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) Start of enrollment: 2013 Oct 14
Completed
Phase 3
Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer Start of enrollment: 2014 May 01
Completed
Phase 2
Expanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple Myeloma
No longer available
Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma Start of enrollment: 2015 Oct 01
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

Clinical Value of Timely Targeted Therapy for Patients With Advanced Non-Small Cell Lung Cancer With Actionable Driver Oncogenes.
Thomas Stricker, Neha Jain, Esprit Ma, Elaine Yu, Rongrong Wang
The Oncologist. 2024-06-03
Improving biomarker testing in advanced non-small-cell lung cancer and metastatic colorectal cancer: experience from a large community oncology network in the USA.
Lee Schwartzberg, Davey Daniel, Daniel Vaena, Dennis Slater, Harry Staszewski
Future Oncology. 2023-06-01
30 citations
Randomized Phase 2 Studies of Checkpoint Inhibitors Alone or in Combination With Pegilodecakin in Patients With Metastatic NSCLC (CYPRESS 1 and CYPRESS 2)
David R. Spigel, Robert M. Jotte, John Nemunaitis, Merrill Kingman Shum, Jeffrey A. Schneider
Journal of Thoracic Oncology. 2021-02-01

Press Mentions

Data at 2020 ASCO Virtual Scientific Program Demonstrates Strength of Nucleix’s Six-Marker Methylation-Based Assay Detecting Broad Array of Early CancersMay 26th, 2020

Professional Memberships

American College of Physicians - ACP
Member